Key result
Atrial fibrillation during hospitalization for acute myocardial infarction independently predicted in-hospital mortality (OR 1.88) compared to patients without atrial fibrillation.
Why the study?
Does the development of atrial fibrillation increase in-hospital mortality and adverse events in patients hospitalized with acute myocardial infarction?
Observational (n=24,658)
Yes
Does the development of atrial fibrillation increase in-hospital mortality and adverse events in patients hospitalized with acute myocardial infarction?
In Chinese patients hospitalized with acute myocardial infarction, the development of atrial fibrillation is associated with significantly higher in-hospital mortality and adverse events, yet anticoagulation remains largely underused.
BACKGROUND: The incidence, clinical outcomes and antithrombotic treatment spectrum of atrial fibrillation (AF) in patients hospitalized with acute myocardial infarction (AMI) have not been well studied in Chinese population. METHODS: Twenty-six thousand five hundred ninety-two consecutive patients diagnosed with AMI were enrolled in CAMI registry from January 2013 to September 2014. After excluding 343 patients with uncertain AF status and 1,591 patients transferred out during hospitalization, 24,658 patients were finally included in this study and involved in analysis. RESULTS: In the CAMI registry, 740 (3.0%) patients were recorded with AF prevalence during hospitalization. Higher-risk baseline clinical profile was observed in patients with AF. These patients were less likely to receive reperfusion/revascularization than those without AF. The in-hospital mortality (including death and treatment withdrawal) was significantly higher in patients with AF than that of without AF (25.2% vs. 7.2%, respectively; p < 0.01). The case of composite of adverse events was similar, which included death, treatment withdrawal, re-infarction, heart failure or stroke (42.1% vs. 16.0%, p <0.01). In multivariate logistic regression analysis, AF was an independent predictor for in-hospital mortality (odds ratio, 1.88; 95% confidence interval: 1.27-2.78) and the composite of adverse events (odds ratio, 2.11; 95% CI: 1.63-2.72). Only 5.1% of patients with AF were treated with warfarin, and 1.7% were treated with both warfarin and dual antiplatelet therapy. CONCLUSIONS: The analysis was based on the CAMI registry in China. The patients hospitalized for AMI who developed AF were at significantly higher risk for in-hospital mortality and other adverse events. However, the anticoagulants including warfarin have been largely underused post hospital discharge. TRIAL REGISTRATION: Clinical Trial Registration: Identifier: NCT01874691 .
No takes yet. Share an insight, caveat, or question.
Dai et al. (2017) conducted an observational in Acute myocardial infarction (n=24,658). Atrial fibrillation vs. No atrial fibrillation was evaluated on In-hospital mortality (death and treatment withdrawal) (OR 1.88, 95% CI 1.27-2.78, p=<0.01). Atrial fibrillation during hospitalization for acute myocardial infarction independently predicted in-hospital mortality (OR 1.88) compared to patients without atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: